{"id":38426,"date":"2025-08-01T20:55:09","date_gmt":"2025-08-01T12:55:09","guid":{"rendered":"https:\/\/flcube.com\/?p=38426"},"modified":"2025-08-01T20:55:10","modified_gmt":"2025-08-01T12:55:10","slug":"allianthera-partners-with-dr-falk-pharma-to-develop-atb102-for-ulcerative-colitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38426","title":{"rendered":"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis"},"content":{"rendered":"\n<p>China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany&#8217;s Dr. Falk Pharma GmbH to jointly develop ATB102, an innovative aryl hydrocarbon receptor (AhR) agonist for the treatment of moderate to severe ulcerative colitis (UC). ATB102, self-developed by AllianThera, is currently in Phase I clinical trials in the United States.<\/p>\n\n\n\n<p><strong>Collaboration Details<\/strong><br>Under the agreement, the two companies will collaborate on advancing the development of ATB102 in the field of inflammatory bowel disease (IBD). Dr. Falk Pharma will have the right to an exclusive global license for manufacturing and commercialization outside of mainland China, Hong Kong, Macau, and Taiwan.<\/p>\n\n\n\n<p><strong>Financial Terms<\/strong><br>AllianThera will receive an upfront payment, development and sales milestone payments, and tiered royalties from Dr. Falk Pharma.<\/p>\n\n\n\n<p><strong>ATB102: A Novel Mechanism-of-Action Therapy<\/strong><br>ATB102 is a gut-enriched AhR agonist that offers a new mechanism of action for IBD treatment. It has the potential to regulate immune homeostasis, repair the mucosal barrier, and provide anti-fibrotic and antioxidant effects. This innovative therapy aims to provide a new option for UC patients who have an inadequate response to or relapse on existing therapies.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany&#8217;s Dr. Falk Pharma GmbH to&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38428,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3881,4263,622],"class_list":["post-38426","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-allianthera-biopharma","tag-dr-falk-pharma","tag-gastroenterology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany&#039;s Dr. Falk Pharma GmbH to jointly develop ATB102, an innovative aryl hydrocarbon receptor (AhR) agonist for the treatment of moderate to severe ulcerative colitis (UC). ATB102, self-developed by AllianThera, is currently in Phase I clinical trials in the United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38426\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis\" \/>\n<meta property=\"og:description\" content=\"China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany&#039;s Dr. Falk Pharma GmbH to jointly develop ATB102, an innovative aryl hydrocarbon receptor (AhR) agonist for the treatment of moderate to severe ulcerative colitis (UC). ATB102, self-developed by AllianThera, is currently in Phase I clinical trials in the United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38426\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T12:55:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-01T12:55:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0105-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis\",\"datePublished\":\"2025-08-01T12:55:09+00:00\",\"dateModified\":\"2025-08-01T12:55:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0105-1.webp\",\"keywords\":[\"AllianThera Biopharma\",\"Dr. Falk Pharma\",\"Gastroenterology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38426#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38426\",\"name\":\"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0105-1.webp\",\"datePublished\":\"2025-08-01T12:55:09+00:00\",\"dateModified\":\"2025-08-01T12:55:10+00:00\",\"description\":\"China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany's Dr. Falk Pharma GmbH to jointly develop ATB102, an innovative aryl hydrocarbon receptor (AhR) agonist for the treatment of moderate to severe ulcerative colitis (UC). ATB102, self-developed by AllianThera, is currently in Phase I clinical trials in the United States.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38426\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0105-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0105-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38426#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis - Insight, China&#039;s Pharmaceutical Industry","description":"China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany's Dr. Falk Pharma GmbH to jointly develop ATB102, an innovative aryl hydrocarbon receptor (AhR) agonist for the treatment of moderate to severe ulcerative colitis (UC). ATB102, self-developed by AllianThera, is currently in Phase I clinical trials in the United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38426","og_locale":"en_US","og_type":"article","og_title":"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis","og_description":"China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany's Dr. Falk Pharma GmbH to jointly develop ATB102, an innovative aryl hydrocarbon receptor (AhR) agonist for the treatment of moderate to severe ulcerative colitis (UC). ATB102, self-developed by AllianThera, is currently in Phase I clinical trials in the United States.","og_url":"https:\/\/flcube.com\/?p=38426","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-01T12:55:09+00:00","article_modified_time":"2025-08-01T12:55:10+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0105-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38426#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38426"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis","datePublished":"2025-08-01T12:55:09+00:00","dateModified":"2025-08-01T12:55:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38426"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38426#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0105-1.webp","keywords":["AllianThera Biopharma","Dr. Falk Pharma","Gastroenterology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38426#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38426","url":"https:\/\/flcube.com\/?p=38426","name":"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38426#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38426#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0105-1.webp","datePublished":"2025-08-01T12:55:09+00:00","dateModified":"2025-08-01T12:55:10+00:00","description":"China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany's Dr. Falk Pharma GmbH to jointly develop ATB102, an innovative aryl hydrocarbon receptor (AhR) agonist for the treatment of moderate to severe ulcerative colitis (UC). ATB102, self-developed by AllianThera, is currently in Phase I clinical trials in the United States.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38426#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38426"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38426#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0105-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0105-1.webp","width":1080,"height":608,"caption":"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38426#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0105-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38426"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38426\/revisions"}],"predecessor-version":[{"id":38429,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38426\/revisions\/38429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38428"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}